Harnessing Nanoparticles for Immunomodulation and Vaccines

The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. T...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 5; no. 1; p. 6
Main Authors Gomes, Ariane C, Mohsen, Mona, Bachmann, Martin F
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 14.02.2017
MDPI
Subjects
Adjuvants
Antigens
Cosmetics
Drug delivery systems
Hepatitis
Hepatitis B
Human papillomavirus
immunogen
Nanoparticles
Review
Vaccines
virus-like particles
Viruses
virus-like particles
immunogen
nanoparticles
vaccines
Online AccessGet full text

Cover

More Information
Summary:The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines5010006